Science Corporation has secured $230.0 million in new funding from investors. The clinical-stage medical technology company is dedicated to restoring quality of life for individuals with debilitating conditions for which current treatment options are limited or non-existent. Science Corporation develops advanced devices aimed at restoring vision, cognition, and mobility to patients who have lost these vital functions. Beyond its direct therapeutic efforts, the company also contributes to the broader medical technology sector through Science Foundry, providing state-of-the-art components and vertically integrated infrastructure for other innovators to build upon.
This significant capital infusion highlights investor confidence in Science Corporation's innovative approach and its potential to address critical unmet medical needs. The company plans to strategically deploy these funds to accelerate its research and development initiatives, advance its ongoing clinical programs, and expand its operational capabilities. With headquarters in Alameda, California, and additional offices in Paris, France, Science Corporation is poised to leverage this investment across its global footprint to drive its ambitious goals.
The investment specifically targets the acceleration of Science Corporation's core mission: bringing its promising medical devices through clinical development and closer to patient availability. A portion of the capital will also support the continued development and expansion of Science Foundry, enhancing its capacity to provide critical infrastructure and components to the broader industry, thereby fostering innovation across the sector.
Looking ahead, Science Corporation aims to further solidify its position as a leader in medical technology innovation. The company anticipates using this funding to bring its promising therapies closer to patients and to scale its infrastructure offerings, driving both internal progress and industry-wide advancements in the pursuit of restoring vital functions and improving patient outcomes.
